You just read:

First-Ever, 36-Month Real-World, Post-Marketing Surveillance Study For IBgard®, A Nonprescription Product For Irritable Bowel Syndrome, Now Peer-Reviewed and Now Accepted For Poster Presentation At Upcoming DDW®, The World's Premier Gastroenterology Conference

News provided by

IM HealthScience

Feb 13, 2020, 11:43 ET